The Role of Fatty Acids in Non-Alcoholic Fatty Liver Disease Progression: An Update

Non-alcoholic fatty liver disease (NAFLD) is a major public health problem worldwide. NAFLD (both simple steatosis and steatohepatitis) is characterized by alterations in hepatic lipid metabolism, which may lead to the development of severe liver complications including cirrhosis and hepatocellular carcinoma. Thus, an exhaustive examination of lipid disorders in the liver of NAFLD patients is much needed. Mass spectrometry-based lipidomics platforms allow for in-depth analysis of lipid alterations in a number of human diseases, including NAFLD. This review summarizes the current research on lipid alterations associated with NAFLD and related complications, with special emphasis on the changes in long-chain and short-chain fatty acids levels in both serum and liver tissue, as well as in the hepatic expression of genes encoding the enzymes catalyzing lipid interconversions.

Automated summary

Non-alcoholic fatty liver disease (NAFLD) is a major global public health problem characterized by alterations in hepatic lipid metabolism that can lead to serious liver complications. Mass spectrometry-based lipidomics platforms allow for in-depth analysis of lipid changes in NAFLD patients, focusing on alterations in long-chain and short-chain fatty acids levels as well as the expression of genes encoding lipid interconversion enzymes in the liver.